GIBSON DUNN

Gibson Dunn Represented Cogent Biosciences in Concurrent Public Offerings of Common Stock and Convertible Notes with Aggregate Gross Proceeds of $575 Million

Firm News | November 17, 2025

Gibson Dunn represented Cogent Biosciences, Inc., a clinical-stage biotechnology company, in concurrent public offerings of common stock and convertible notes expected to result in aggregate gross proceeds of $575 million to Cogent.

J.P. Morgan Securities, Jefferies, Leerink Securities, and Guggenheim Securities acted as joint book-running managers for the equity offering, with LifeSci Capital acting as lead manager and Raymond James Acting as co-manager. Jefferies and J.P. Morgan Securities acted as joint book-running managers for the notes offering.

Our team included partners Ryan Murr, Branden Berns, and Stewart McDowell and associates Nick Linke, Candice Johnson, and Jasmine Vitug.

Related People

Ryan A. Murr

Branden C. Berns

Stewart McDowell

Nicholas G. Linke

Candice D. Johnson

Jasmine L. Vitug

Related Capabilities

Life Sciences

© 2026 Gibson, Dunn & Crutcher LLP. All rights reserved. For contact and other information, please visit us at www.gibsondunn.com. | **www.gibsondunn.com**